PT2977
Phase 2- Indications
- Renal cell carcinoma, von Hippel-Lindau disease, Glioblastoma multiforme
Company intelligence / Profile preview
Peloton Therapeutics, Inc.
Dallas, Texas, United Statesorpha.net ↗
- Ownership
- Private
- Employees
- ~64
- Development stage
- Phase 2
01
Overview
Peloton’s lead candidate PT2977 demonstrated a partial response rate of 24% and an overall clinical benefit rate of 78% in previously treated mRCC patients. At a median follow-up of about ten months, progression-free survival probability was approximately 50%. The company also had ongoing studies combining PT2977 with cabozantinib and exploring use in glioblastoma. A second compound, PT2567, was being developed preclinically for non-oncology indications such as PAH
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small molecules (notably oral HIF‑2α inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Exelixis on combination trials with cabozantinib
Beyond the preview
Go deeper on Peloton Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peloton Therapeutics, Inc..